Amendment of Statement of Principles concerning acquired cataract No. 33 of 2002

Overview

This legislative instrument, numbered 33 of 2002, represents an amendment by the Repatriation Medical Authority under the Veterans’ Entitlements Act 1986, aiming to refine the Statement of Principles concerning acquired cataractic conditions. Specifically, this amendment deletes the definition of “diabetes mellitus” from paragraph 8, as originally set out in Instrument No. 38 of 2001. The purpose of this change is to align the legislative framework more precisely with current medical understandings and diagnostic criteria, thereby ensuring that veterans’ claims are assessed based on the most accurate and relevant information. The amendment applies comprehensively to all matters governed by Instrument No. 38 of 2001 and section 120B of the Act, reflecting a commitment to maintaining the integrity and fairness of the benefits system for veterans.

Scope and Application

The Legislative Instrument No.33 of 2002, made under the Veterans’ Entitlements Act 1986, pertains specifically to the amendment of the Statement of Principles concerning acquired cataracts, which are coded under H25, H26, H28.1, and H28.2. The Repatriation Medical Authority, exercising its powers under subsection 196B(3) of the Act, modifies Instrument No.38 of 2001 by removing the definition of "diabetes mellitus." This amendment impacts all matters to which Instrument No.38 of 2001 and section 120B of the Act apply, thereby affecting veterans and their entitlement claims related to cataracts. The amendment does not extend to other conditions or definitions within the broader scope of the Veterans’ Entitlements Act, ensuring that its application remains narrowly focused on the specified medical conditions and the removal of the referenced definition. This legislative instrument operates within the Commonwealth jurisdiction, directly impacting the administration of veterans' benefits and entitlements.

Key Provisions

The legislative instrument (F2005B02502) amends Instrument No.38 of 2001 concerning the Statement of Principles regarding acquired cataractic conditions under the Veterans' Entitlements Act 1986. Specifically, the amendment involves the removal of the definition of “diabetes mellitus” from paragraph 8 (Section 1). This amendment aims to refine the scope and application of the principles governing acquired cataractic conditions, which are listed under codes H25, H26, H28.1, and H28.2 in the Act. Under the Veterans’ Entitlements Act 1986, the Repatriation Medical Authority is responsible for issuing and amending Statements of Principles that define conditions covered under the Act. The obligation of the Authority in this instance is to ensure that the principles accurately reflect the current understanding of medical conditions, including the removal of outdated or unnecessary definitions. This ensures that the legal framework remains relevant and effective in addressing the needs of veterans (Section 196B(3)). The Act imposes certain obligations on the Repatriation Medical Authority to periodically review and update the Statements of Principles. This includes the responsibility to consult with relevant medical experts and stakeholders to ensure the principles are accurate and comprehensive. Additionally, the Authority must ensure that any amendments are communicated effectively to all parties affected by the changes, including veterans and their representatives (Section 196B(3)). Failure to comply with the requirements of the Veterans' Entitlements Act 1986 can lead to various legal consequences. For example, if the Repatriation Medical Authority does not accurately and timely update the Statements of Principles, it may result in legal challenges or appeals from affected veterans. The Act does not explicitly state penalties for non-compliance, but the potential for litigation and reputational damage to the Authority can be significant. The consequences can include financial liabilities and the need for additional legal defence in court proceedings (Section 196B(3)).